VTE Risk Not Elevated in AD Patients on JAK Inhibitors: Study

Investigators examined the VTE risk in untreated patients with AD versus those without AD, compared with AD patients treated with JAK-inhibitors versus those on placebo or dupilumab.
MDedge News

source https://www.medscape.com/viewarticle/979966?src=rss